Replies to post #97198 on Biotech Values

[ghmm]

Is there a criteria for making the cut on this list?
http://clinicaltrials.gov/ct2/show/study/NCT01132313

[DewDiligence]

Who’s Who in All-Oral HCV Programs

[New table format includes columns for dosing frequency, use
of ribavirin, and links to clinicaltrials.gov; added B-I program.]

 
          Protease     Other      Non-PI    Arms w     Dosing 
 Company  Inhibitor   Compound    Class    Ribavirin  Frequency  Link 
 VRTX     Telaprevir  VX-222     non-nuke    some       BID      http://clinicaltrials.gov/ct2/show/NCT01080222 
 Roche    ITMN-191    RG7128       nuke      none      TID/BID   http://clinicaltrials.gov/ct2/show/NCT00801255 
 BMY      BMS-650032  BMS-790052   NS5A      some       BID      http://clinicaltrials.gov/ct2/show/NCT01012895 
 GILD     GS9256      GS9190     non-nuke    some       BID      http://clinicaltrials.gov/ct2/show/NCT01072695 
 B-I      BI 201335   BI 207127  non-nuke    all       TID/BID   http://clinicaltrials.gov/ct2/show/NCT01132313 
 IDIX     IDX320      IDX184       nuke      TBD         qD      *

*Drug-drug-interaction study expected to start Jul/Aug 2010.

[mcbio]

Re: Who's Who in All-Oral HCV Programs

I think we can now add ACHN to this list with the announcement of the NS5A inhibitor today. ACHN will also share with IDIX the important point of potentially having the only combo with the potential for QD dosing. Obviously, ACH-1625 does not work on all genotypes but the potential is there for ACH-2684 to do so.